Gadobutrol (Gadobutrol) Patent Expiration, LOE Window & CMS Spending
Gadobutrol (Gadobutrol) by Fresenius Kabi: Multi-Source Generic Molecule, 2 AB generics, $482K 2024 CMS Part D & Medicaid spend, and $1,743 CA SB 17 specialty launch WAC.
| Regulatory & Reimbursement Dimension | Verified Value |
|---|---|
| Consolidated Sponsor | Fresenius Kabi |
| FDA Application & Pathway | Reconciled (ANDA) |
| Exclusivity / Cliff Horizon | Multi-Source Generic Molecule |
| Core Active-Ingredient LOE Date | Not listed / N/A |
| Last Listed Patent or Exclusivity Date | Not listed / N/A |
| Orange Book Patents (*PED Extensions) | 0 patents (0 *PED) |
| Active AB-Rated Generic Competitors | 2 |
| 2024 CMS Total Public Spend | $482K |
| 2024 Medicare Part D Spend | $0 |
| 2024 Medicaid Spend | $482K |
| Reported Wholesale Price Change (CA SB 17) | Specialty launch notice ($1,743 intro WAC) |
Related Filings Across Meru Platforms
Verified cross-ledger federal filings for Fresenius / Fresenius Kabi across sibling Meru public-data platforms.